SCHEMBL3460244

SCHEMBL3460244

COCCOc1cccc([N+](=O)[O-])c1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.68
CHRNA4 P43681 1/20 0.68
HPGD P15428 2/20 0.55
LMNA P02545 2/20 0.55
CHRNB4 P30926 1/20 0.54
CHRNA3 P32297 1/20 0.54
MAPT P10636 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MAOB P27338 1/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
LTA4H P09960 1/20 0.50
PTGS2 P35354 1/20 0.50
TSHR P16473 1/20 0.50
POLB P06746 1/20 0.49
GRM5 P41594 1/20 0.49
MAPK1 P28482 1/20 0.49
RECQL P46063 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30833154 1.00 CHRNB2 (0.68) CHRNB2CHRNA4HPGDLMNACHRNB4
SCHEMBL15720996 0.95 CHRNB2 (0.63) CHRNB2CHRNA4HPGDLMNACHRNB4
SCHEMBL2063354 0.92 CHRNB2 (0.67) CHRNB2CHRNA4HPGDLMNACHRNB4
SCHEMBL15498199 0.92 CHRNB2 (0.73) CHRNB2CHRNA4HPGDLMNACHRNB4
SCHEMBL2374109 0.85 CHRNB2 (0.70) CHRNB2CHRNA4HPGDLMNACHRNB4
SCHEMBL4701140 0.85 CHRNB2 (0.61) CHRNB2CHRNA4HPGDLMNACHRNB4
SCHEMBL14028449 0.85 CHRNB2 (0.69) CHRNB2CHRNA4HPGDLMNACHRNB4
SCHEMBL29547480 0.84 CHRNB2 (0.65) CHRNB2CHRNA4HPGDLMNACHRNB4
SCHEMBL17905717 0.84 CHRNB2 (0.68) CHRNB2CHRNA4HPGDLMNACHRNB4
SCHEMBL8957329 0.84 CHRNB2 (0.64) CHRNB2CHRNA4HPGDLMNACHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117677613-A Process for producing synthetic intermediate of monocyclic pyridine derivative 卫材R&D管理有限公司 2024-03-08 CN disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20170029367-A1 Substituted Aromatic Sulfur Compounds and Methods of Their Use CEPHALON INC (US) 2017-02-02 US disclosed
US-9475766-B2 Substituted aromatic sulfur compounds and methods of their use CEPHALON, INC. (US) 2016-10-25 US disclosed
US-20140005175-A1 Substituted Aromatic Sulfur Compounds and Methods of Their Use CEPHALON, INC. (US) 2014-01-02 US disclosed
WO-2012116151-A2 SUBSTITUTED AROMATIC SULFUR COMPOUNDS AND METHODS OF THEIR USE CEPHALON, INC. (US) 2012-08-30 WO disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
EP-1807419-B1 (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2009-05-27 EP disclosed
US-5023255-A Triazine derivatives; inhibitors exzyme 5-lipoxygenase GLAXO GROUP LIMITED (GB) 1991-06-11 US disclosed
EP-0388165-A2 Chemical compounds GLAXO GROUP LIMITED (GB) 1990-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 CHRNB2 4800/4885CHRNA4 4773/4885HPGD 2406/4885
US-20140005175-A1 Substituted Aromatic Sulfur Compounds and Methods of Their Use RB1, NRAS, TP53 CHRNB2 4597/4885CHRNA4 4880/4885HPGD 942/4885
US-20170029367-A1 Substituted Aromatic Sulfur Compounds and Methods of Their Use RB1, NRAS, TP53 CHRNB2 4597/4885CHRNA4 4880/4885HPGD 942/4885
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B CHRNB2 2290/4885CHRNA4 1971/4885HPGD 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.